Table 4. Blood parameters and vascularisation; prostate size ≥ 70 mL.
Group A ≥ 70 mL (placebo) | Group B ≥ 70 mL (dutasteride) | p value | |
Hemoglobin before HoLEP, (g/dl) ± SD | 14.14 ± 2.02 | 14.21 ± 2.31 | 0.48 |
Hemoglobin after HoLEP, (g/dl) ± SD | 12.40 ± 1.99 | 12.52 ± 2.11 | 0.49 |
ΔHb ±SD | 1.74 ± 0.22 | 1.69 ± 0.17 | |
Hematocrit before HoLEP, % ± SD | 43.02 ± 3.89 | 42.59 ± 3.43 | 0.64 |
Hematocrit after HoLEP, % ± SD | 40.19 ± 4.00 | 40.25 ± 3.77 | 0.77 |
ΔHt ±SD | 2.83 ± 0.54 | 2.34 ± 0.49 | |
MVD | 26.83 ± 2.12 | 20.76 ± 0.79 | < .05 |
VEGF index | 8.54 ± 1.18 | 3.21 ± 0.54 | < .05 |
HoLEP: Holmium Laser Enucleation of the Prostate; MVD: microvascular density; VEGF index: vascular endothelial growth factor index; SD: standard deviation.